[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International Plc LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 126.50 123.00 130.00 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.5 -0.6 -4.7 - 20

Aortech Share Discussion Threads

Showing 8551 to 8573 of 8900 messages
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
DateSubjectAuthorDiscuss
31/3/2020
09:42
Looks like the 1491 shares bought yesterday at 66.2 have just been offloaded at 66.35. Why do people bother? AOR is hardly a trading stock with the sorts of spreads we see normally.
langland
30/3/2020
16:34
Nice to hear that one of the core devices (cannula) that currently uses Elasteon is providing vital assistance in the care of seriously ill Covid19 patients. All grist to the mill in support of the benefits of Elasteon polymers in medical devices.
bones
30/3/2020
16:07
Fair play to the management here. They have been as positive as they can be in the circumstances.
langland
30/3/2020
16:02
Good to see confirmation of the group’s importance to the medical device world and it is sensible for David Richmond to agree to part defer the cash element. Sounds like R&D efforts are full speed ahead re grafts and heart valve.
bones
30/3/2020
15:52
Sensible moves in RNS.
semper vigilans
27/3/2020
16:02
Bones: I think Europe is slowly turning the virus corner so should not be too long for the "back to work bounce" -
netcurtains
27/3/2020
15:54
Hmmm, 60p to buy. Who would have thunk it!
bones
24/3/2020
18:18
Well I seemed to have been right - for at least one day.... Wish I took my own advice.
netcurtains
24/3/2020
12:30
I’m not sure, still see some general downside from here but hope springs eternal... Gla
andyview
24/3/2020
12:24
Apparently we're at the peak depression point in the stock market gloom..... Be interesting if its NORTH more or less from now.
netcurtains
20/3/2020
09:22
A few buyers retuning here today, i added a few more yesterday gla
andyview
19/3/2020
13:42
Following up on amt’s comments, it is not RUA that is “getting a good deal”, but David Richmond, who is the person selling RUA Medical Devices Ltd to Aortech. Whether you regard it as “a good deal” for him is up to you but what is clear to me is that Aortech has acquired all of the assets I referred to in my last post and, very pertinent in my view, David Richmond becomes a near 10% shareholder in Aortech as well as the CEO of the group (soon to be known as RUA Life Sciences plc). A new CEO, with a history of entrepreneurial success in the company’s exact line of work and much skin in the game to boot is yet another valuable asset going forward. I hope he shakes it up!
bones
19/3/2020
08:02
amt remember that they are receiving shares at £1 which can now be bought at just over half of that value. It was a great deal for AOR shareholders IMHO
parsons4
19/3/2020
05:45
It looks to me like RUA are getting a good deal. They will receive.. 95m in cash plus rest in shares for a company valued at 2.45m. Small companies like these have seen values more than halve in the stock market crash so if it was a quoted company it might only be valued at. 95m now so they are getting AOR shares for free or not very much anyway.
amt
19/3/2020
05:36
Just read through, once again, the recent news. This is really looking very good on a 12 to 18 month view and of course onwards. A bright spot in the carnage going on at the moment. Two sellers of 5000 shares was all it took to reduce the price, the cap is now £9.5m after the recent deal, a gift !! not much downside from here I believe, tempted to top up this am !!!! as you say bones just a waiting game.
parsons4
15/3/2020
21:22
I have been reviewing once more the recent research note by Equity Development (that attributed a valuation of 676p to AOR) and the recent RNS outlining the proposed acquisition of RUA Medical and subsequent reorganisation of the group into divisional subsidiaries (all very sensible in my book). It is always easy to read too much into things written but small paragraphs that jump out to me question their meanings or intentions to inform. In particular, in the ED research note, under the section on the Heart Valve division, there is this observation: ”We understand that AorTech has been in dialogue with potential licensors of its heart valve in order to use trial providers, designs and models that large medical device companies regard as validation for this type of product.” I note that this refers to using trial providers etc that have the blessing of the potential licensor majors which suggests some kind of licensing interaction before trials happen whereas I was thinking that majors would not be interested in any licensing before some kind of trial results had already been obtained. I dare say it is more subtle than this in reality but I go by what I read in the note. To enable such a thing to happen, it would be necessary to untangle all of the historic IP, patents and whatnot relating to the heart valve from everything else “Elast-EonR21;-related in the Aortech group, hitherto scrambled up in the one company, Aortech International plc. Then we have the new RUA proposals, amongst which is the intention to divisionalise all aspects of the previously tangled-up parts of Aortech, soon to be RUA Life Sciences plc. One part of the new structure will be the creation of “RUA Structural Heart”. An excerpt from The Chairman’s Letter dated 11th March 2020 says: ”Following Completion, AorTech Heart Valve Technologies Limited, a non-trading subsidiary of AorTech, will change its name to RUA Structural Heart and it is planned that it will hold the intellectual property relating to the Company’s synthetic heart valve.” This would ensure that the ducks are organised into the correct row in the event that the “understandings” expressed in the Equity Development research note ever come to pass. I guess we will see in time!
bones
14/3/2020
00:02
It's also a 85% discount to the recent analyst valuation If this becomes a Billion pound company I'm not going to begrudge him making 100m though
the stigologist
13/3/2020
17:03
GR, in this market, the answer is a resounding “NO”! In such a bear market environment, Aortech (soon to be RUA Life Sciences) would have to throw some tasty fishes to the sharks to whet their appetites. New licence deals, tangible advances in trials, maybe even some kind of investment from a life science or medtech fund; something concrete for (now less speculative and more reluctant) investors to grasp. Nothing else will do in such a rough market! Otherwise, it is a patient waiting game, something that we all know is the nature of this particular investment, necessarily. At some point in the future, the stars here will align, then we could have take-off.
bones
13/3/2020
09:26
So the RUA owner, the chap who knows both RUA and AOR the best is prepared to accept shares at a premium of 34% to the market but no-one else cares?
greedy rooster
11/3/2020
15:43
Great stuff bones. We just need the Covid-19 noise to subside. TMK
tees maar khan
11/3/2020
15:10
This merging of businesses under the Aortech umbrella makes a lot of sense and no surprise really. The two entities were clearly liking each other’s contributions to the respective businesses. It’s also pleasing to see the PLC board and senior management beefed up, especially separating the Executive Chairman and CEO roles. I think that is something the market should give more credit for, because (1) it provides better governance and (2) the new CEO also has a long history in the medical device industry and is an entrepreneurial and driven person (based on my meeting and talking with him at the AGM). He can take some of the pressure off Bill Brown’s shoulders and, between them, ramp up the promotion of the company on both the operational and investor sides. It is also good to bring some very profitable, ready made, business into the PLC group to provide immediate positive cash flow. Within the larger PLC set up, the proposition should also be more attractive to potential future customers, I would have thought. The PLC balance sheet will now also contain freehold property (which banks always like to see as solid security if required) and additional cash and retained profits already sitting in RUA’s balance sheet. Finally, I like the new proposed structure with a holding company holding separate divisions via subsidiaries. This enables clear distinction between divisions and ultimately separate assets/businesses that could be spun off or sold as they develop. Clearly, in the current bear market, ownership of even the Crown Jewels on a 2-for-1 basis would see the share price marked down!
bones
11/3/2020
12:39
I've added a few, please don't say anything else temper ;-)) gla
andyview
11/3/2020
12:37
I’m tempted to buy a few more but that normally has a further negative impact on an share price
semper vigilans
Chat Pages: Latest  344  343  342  341  340  339  338  337  336  335  334  333  Older
ADVFN Advertorial
Your Recent History
LSE
AOR
Aortech
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210918 05:56:38